RESEARCH ARTICLEOpen Access
CHD1L Protein is overexpressed in human
ovarian carcinomas and is a novel predictive
biomarker for patients survival
Wei-Peng He1, Juan Zhou1, Mu-Yan Cai2, Xiang-Shen Xiao2, Yi-Ji Liao2, Hsiang-Fu Kung3, Xin-Yuan Guan2,
Dan Xie2and Guo-Fen Yang1*
Background: Our recent studies suggested that the chromodomain helicase DNA binding protein 1-like (CHD1L)
gene plays an oncogenic role in human hepatocellular carcinoma. However, the status of CHD1L protein expression
in ovarian cancer and its clinical/prognostic significance are obscure.
Methods: In this study, immunohistochemistry (IHC) for CHD1L was performed on a tissue microarray (TMA)
containing 102 primary ovarian carcinomas and 44 metastatic lesions (omental metastasis). Receiver-operator curve
(ROC) analysis was used to evaluate patients’ survival status.
Results: There is an augmented tendency of CHD1L expression in ovarian carcinoma metastasis than in primary
lesions (P<0.05). A significant association was found between positive expression of CHD1L and tumors histological
type (P <0.05). By univariate survival analysis of the ovarian carcinoma cohorts, positive expression of CHD1L was
significantly correlated with shortened patient survival (mean 66.7 months versus 97.4 months, P<0.05). Moreover,
CHD1L expression was evaluated to be a significant and independent prognostic factor in multivariate analysis
Conclusions: These findings provide evidence that positive expression of CHD1L protein is significantly correlated
with the metastasis proceeding of ovarian carcinoma, and CHD1L protein expression, as examined by IHC, may act
as a novel prognostic biomarker for patients with ovarian carcinoma.
Ovarian cancer, the leading cause of death from a
gynecological malignancy, has increasing incidence re-
cently in China and Singapore . The onset age for
ovarian cancer is about 45 years old . On account of
the absence of early diagnosis methods and the absence
of characteristic symptoms, the majority of ovarian can-
cer patients (70%) were diagnosed at FIGO III/IV, and
had a unfavorable prognosis with a 5-year survival rate
of <20% . Recently, ovarian cancer was considered as
a more complicated genetic change and multiple-step
patho-physiological change . Clinically, most ovarian
cancers are ovarian carcinoma. It is prevalent to
discovery a tumor marker for the diagnosis and progno-
sis of ovarian carcinoma, as well as developing targeted
therapy, predicting the survival, and predicting relapse.
Recently, we reported that the chromodomain helicase
DNA binding protein 1-like (CHD1L) gene is a putative
oncogene mapped to chromosome 1q21 and it is asso-
ciated with hepatocellular carcinoma (HCC) tumorigen-
esis . CHD1L belongs to SNF-2family, which contains
a domain (approximately 400 amino acids) with highly
conserved helicase motifs . The full-length mRNA
(2.98kb) of CHD1L encodes an 897aa protein. Most
SNF2-like proteins participate in various nuclear activ-
ities, such as transcriptional activation or repression,
DNA repair and recombination [6,7]. In HCC patients,
over 50% cases have overexpression of CHD1L, which is
associated with the carcinoma progression and metasta-
sis and predict the poor prognosis of the survival status
* Correspondence: firstname.lastname@example.org
1Department of Gynecology, the First Affiliated Hospital, Sun Yat-Sen
University, No. 78, Zhongshan Road II, 510080 Guangzhou, China
Full list of author information is available at the end of the article
© 2012 He et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
He et al. BMC Cancer 2012, 12:437
8. Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, Wang J, Dong SS, Tang KH,
Xie D, Li Y, Guan XY: CHD1L promotes hepatocelluar carcinoma
progressio and metastasis in mice and is associated with these
processes in human patients. J Clin Invest 2010, 120:1178–1188.
Xie D, Sham JST, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y, Hu L,
Guan XY: Heterogeneous expression and association of β-catenin, p16
and c-myc in multistage colorectal tumorigenesis and progression
detected by tissue microarray. Int J Cancer 2003, 107:896–902.
Yang GF, Li XM, Xie D: Overexpression of clusterin in ovarian cancer is
correlated with impaired survival. Int J Gynecol Cancer 2009, 19:1342–1346.
Yang GF, He WP, Cai MY, Li-Ru H, Jun-Hang L, Hai-Xia D, Xin-Yuan G, Mu-
Sheng Z, Yi-Xin Z, Dan X: Intensive expression of Bmi-1 is a new
independent predictor of poor outcome in patients with ovarian
carcinoma. BMC Cancer 2010, 10:133.
Chen L, Yuan YF, Li Y, Chan TH: Clinical significance of CHD1L in
hepatocellular carcinoma and therapeutic potentials of virus-mediated
CHD1L depletion. Gut 2011, 60:534–543.
Ng IO, Srivastava G, Chung LP: Overexpression and point mutations of
p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong
Chinese people. Cancer 1994, 74:30–37.
Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, Tang DJ, Fu L, Wu Z, Chen
M, Fang Y, Guan XY: Isolation and characterization of a novel oncogene,
amplified in liver cancer 1, within a commonly amplified region at 1q21
in hepatocellular carcinoma. Hepatology 2008, 47:503–510.
Gronwald J, Störkel S, Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A,
Lubinski J, Cremer T: Comparison of DNA gains and losses in primary renal
clear cell carcinomas and metastatic sites: importance of 1q and 3p copy
number changes in metastatic events. Cancer Res 1997, 57:481–487.
Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M: PetersenI:
Chromosomal alterations in the clonal evolution to the metastaticstage
of squamous cell carcinomas of the lung. Br J Cancer 2000, 82:65–73.
Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, Yamamoto K,
Ishii K, Kita T, Kikuchi Y, Nagata I, Miwa M, Uchida K: Gains of 1q21-q22 and
13q12-q14 are potential indicators for resistance to cisplatin-based
chemotherapy in ovarian cancer patients. Clin Cancer Res 1999, 5:2526–2531.
Hirai M, Yoshida S, Kashiwagi H, Kawamura T, Ishikawa T, Kaneko M, Ohkawa
H, Nakagawara A, Miwa M, Uchida K: 1q23 gain is associated with
progressive neuroblastoma resistant to aggressive treatment.
Genes Chromosomes Cancer 1999, 25:261–269.
Deng W: PARylation:strengthening the connection between cancer and
pluripotency. Cell Stem Cell 2009, 10:349–350.
Cite this article as: He et al.: CHD1L Protein is overexpressed in human
ovarian carcinomas and is a novel predictive biomarker for patients
survival. BMC Cancer 2012 12:437.
Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
He et al. BMC Cancer 2012, 12:437
Page 8 of 8